整合磷酸化蛋白质组学与转录分类器揭示多发性骨髓瘤中隐藏的RAS信号动态
本研究采用整合磷酸化蛋白质组学和转录组分析的系统方法解析多发性骨髓瘤(MM)细胞信号,发现RAS下游效应器活性因细胞系基因型而异,并利用CoMMpass患者转录组数据建立机器学习分类器,揭示NRAS与KRAS突变肿瘤转录输出显著不同,高MAPK患者(富集NRAS Q61突变)预后更差,而RAS突变整体无生存影响。
要点
- RAS突变整体对MM生存无影响,但高MAPK转录特征患者(富集NRAS Q61突变)预后更差。
- NRAS与KRAS突变肿瘤转录输出显著不同,基因组景观无法揭示这种功能信号差异。
- 突变Ras是选择性脆弱点,而其他MAPK通路基因并非如此。
核心结论
- 整合磷酸化蛋白质组学和转录组分析揭示MM中RAS信号动态,NRAS与KRAS突变肿瘤转录输出显著不同,高MAPK患者预后更差。
研究设计与样本
- 研究采用整合磷酸化蛋白质组学和转录组分析的系统方法,并在CoMMpass研究患者转录组数据中应用机器学习分类器。
主要发现
- 无偏磷酸化蛋白质组学揭示MM细胞系间激酶差异激活,mTOR抑制剂敏感性可能尤其依赖mTOR激酶基线活性。
- Ras下游效应器活性因细胞系基因型而异。
- 机器学习分类器识别NRAS与KRAS突变肿瘤转录输出显著不同。
- 遗传依赖性和基因表达分析显示突变Ras是选择性脆弱点,而非其他MAPK通路基因。
- 转录分析提示异常MAPK通路激活仅见于部分RAS突变患者(对比野生型RAS),高MAPK患者富集NRAS Q61突变且预后更差,而RAS突变整体无生存影响。
临床怎么用
- 基于转录特征的分类可改进MM精准医学试验中的患者分层,识别高MAPK脆弱信号患者。
- developed交互式软件工具关联骨髓瘤中药理与遗传激酶依赖性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A major driver of multiple myeloma (MM) is thought to be aberrant signaling, yet no kinase inhibitors have proven successful in the clinic. Here, we employed an integrated, systems approach combining phosphoproteomic and transcriptome analysis to dissect cellular signaling in MM to inform precision medicine strategies. Unbiased phosphoproteomics initially revealed differential activation of kinases across MM cell lines and that sensitivity to mammalian target of rapamycin (mTOR) inhibition may be particularly dependent on mTOR kinase baseline activity. We further noted differential activity of immediate downstream effectors of Ras as a function of cell line genotype. We extended these observations to patient transcriptome data in the Multiple Myeloma Research Foundation CoMMpass study. A machine-learning-based classifier identified surprisingly divergent transcriptional outputs between NRAS- and KRAS-mutated tumors. Genetic dependency and gene expression analysis revealed mutated Ras as a selective vulnerability, but not other MAPK pathway genes. Transcriptional analysis further suggested that aberrant MAPK pathway activation is only present in a fraction of RAS-mutated vs wild-type RAS patients. These high-MAPK patients, enriched for NRAS Q61 mutations, have inferior outcomes, whereas RAS mutations overall carry no survival impact. We further developed an interactive software tool to relate pharmacologic and genetic kinase dependencies in myeloma. Collectively, these predictive models identify vulnerable signaling signatures and highlight surprising differences in functional signaling patterns between NRAS and KRAS mutants invisible to the genomic landscape. These results will lead to improved stratification of MM patients in precision medicine trials while also revealing unexplored modes of Ras biology in MM.
引用
- Lin YT, Way GP, Barwick BG, et al. Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma. Blood Adv. 2019. PMID: 31698452. doi:10.1182/bloodadvances.2019000303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。